High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

INTRODUCTION: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV is affected by DCV resistance-associated polymorphisms (RAPs) in HCV NS5A...

Descripción completa

Detalles Bibliográficos
Autores principales: McPhee, Fiona, Suzuki, Yoshiyuki, Toyota, Joji, Karino, Yoshiyasu, Chayama, Kasuaki, Kawakami, Yoshiiku, Yu, Min Lung, Ahn, Sang Hoon, Ishikawa, Hiroki, Bhore, Rafia, Zhou, Nannan, Hernandez, Dennis, Mendez, Patricia, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522028/
https://www.ncbi.nlm.nih.gov/pubmed/26155891
http://dx.doi.org/10.1007/s12325-015-0221-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522028/
https://www.ncbi.nlm.nih.gov/pubmed/26155891
http://dx.doi.org/10.1007/s12325-015-0221-5

Ejemplares similares